Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Decreased microglial activation in MS patients treated with glatiramer acetate.
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
Cladribine
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
TGN1412: From Discovery to Disaster.
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Glatiramer acetate during early pregnancy: A prospective cohort study.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
EFNS 2012

Pages